帕博利珠单抗联合化疗治疗PD-L1阳性HR+/HER2-晚期乳腺癌:KEYNOTE-B49 III期研究最终分析
KEYNOTE-B49研究评估帕博利珠单抗联合化疗对比安慰剂联合化疗在PD-L1阳性(CPS≥1)HR+/HER2-晚期乳腺癌患者中的疗效。342例患者随机分组,中期分析显示联合组无进展生存期显著改善(HR 0.74,95%CI 0.58-0.95,P=0.0089),但最终分析总生存期无显著获益(HR 1.04,95%CI 0.81-1.33,P=0.6185)。
要点
- PD-L1 CPS≥1人群,帕博利珠单抗联合化疗显著改善PFS,HR 0.74。
- PD-L1 CPS≥10人群PFS HR 0.59,数值上 favoring 联合组。
- 最终分析OS无显著改善,HR 1.04。
核心结论
- 在PD-L1阳性(CPS≥1)HR+/HER2-晚期乳腺癌患者中,帕博利珠单抗联合化疗较安慰剂联合化疗显著改善PFS,未观察到新的安全性信号。
- 最终分析未观察到OS显著改善。
研究设计与样本
- III期随机对照研究KEYNOTE-B49,纳入342例既往内分泌治疗后进展、适合一线化疗的PD-L1 CPS≥1的HR+/HER2-局部复发不可手术或转移性乳腺癌患者。
- 随机接受帕博利珠单抗200 mg或安慰剂每3周一次联合化疗。
- 主要终点为盲态独立中心评估的PFS(RECIST v1.1),关键次要终点为OS。
- 因PD-L1阳性率低,方案修订后缩减了样本量。
主要发现
- 中期分析(中位随访29.1个月),PFS的HR为0.74(95%CI 0.58-0.95;P=0.0089,达到显著性标准), favoring 帕博利珠单抗联合化疗组,中位PFS分别为6.7个月(95%CI 6.2-8.3)和6.0个月(95%CI 4.2-8.1)。
- PD-L1 CPS≥10人群PFS的HR为0.59(95%CI 0.35-0.98),数值上 favoring 帕博利珠单抗联合化疗。
- 最终分析(中位随访34.9个月),OS的HR为1.04(95%CI 0.81-1.33;P=0.6185),中位OS分别为21.0个月(95%CI 18.9-22.9)和22.2个月(95%CI 17.6-26.3)。
- 帕博利珠单抗联合化疗组≥3级治疗相关不良事件发生率为38%,安慰剂联合化疗组为33%;因治疗相关不良事件停药的比例分别为11%和5%。
关键数值与推荐
- PD-L1 CPS≥1人群PFS HR 0.74(95%CI 0.58-0.95;P=0.0089)。
- PD-L1 CPS≥10人群PFS HR 0.59(95%CI 0.35-0.98)。
- OS HR 1.04(95%CI 0.81-1.33;P=0.6185)。
- ≥3级治疗相关不良事件:联合组38%,对照组33%;因治疗相关不良事件停药:11% vs 5%。
临床怎么用
- 对于PD-L1阳性(CPS≥1)HR+/HER2-晚期乳腺癌经内分泌治疗后进展的患者,帕博利珠单抗联合化疗可考虑作为改善PFS的治疗选择。
- 需权衡PFS获益与OS无显著改善及免疫相关不良事件风险,进行个体化决策。
局限性
- 因PD-L1阳性率低,方案修订后样本量缩减。
- 最终分析未显示OS获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated pembrolizumab plus chemotherapy versus chemotherapy alone in participants with PD-L1‒positive, hormone receptor-positive (HR+)/HER2- advanced breast cancer after progression on prior endocrine-based therapy (ET). PATIENTS AND METHODS: Participants with locally recurrent inoperable or metastatic HR+/HER2- breast cancer with PD-L1 combined positive score (CPS) ≥1 who had prior ET and were candidates for first-line chemotherapy were randomized to pembrolizumab 200 mg or placebo Q3W plus chemotherapy. The primary and key secondary endpoints were progression-free survival (PFS) per RECIST v1.1 by blinded independent central review and overall survival (OS), respectively, in participants with PD-L1 CPS ≥1. PFS and OS in participants with PD-L1 CPS ≥10 and safety were secondary endpoints. Following protocol amendment, the sample size was reduced due to low PD-L1 prevalence. RESULTS: 342 participants were randomized. At interim analysis (median follow-up, 29.1 months), the hazard ratio (HR) for PFS was 0.74 (95% CI, 0.58‒0.95; P=0.0089 [significance criterion met]) favoring pembrolizumab plus chemotherapy versus placebo plus chemotherapy (median [95% CI] PFS, 6.7 [6.2‒8.3] versus 6.0 [4.2‒8.1] months). HR for PFS in participants with PD-L1 CPS ≥10 numerically favored pembrolizumab plus chemotherapy (0.59; 95% CI, 0.35‒0.98). At final analysis (median follow-up, 34.9 months), HR for OS was 1.04 (95% CI, 0.81‒1.33; P=0.6185) for pembrolizumab plus chemotherapy versus placebo plus chemotherapy (median [95% CI] OS, 21.0 [18.9‒22.9] versus 22.2 [17.6‒26.3] months). Grade ≥3 treatment-related AEs occurred in 38% of participants in the pembrolizumab plus chemotherapy arm and 33% in the placebo plus chemotherapy arm; 11% and 5% discontinued treatment due to treatment-related AEs, respectively. CONCLUSION: In participants with PD-L1‒positive (CPS ≥1) HR+/HER2- advanced breast cancer, pembrolizumab plus chemotherapy demonstrated statistically significant improvement in PFS, with no new safety signals observed. A numerical effect favoring pembrolizumab plus chemotherapy for PFS was observed in participants with PD-L1 CPS ≥10. No significant OS improvement was observed. CLINICAL TRIAL REGISTRATION: KEYNOTE-B49; ClinicalTrials.gov, NCT04895358.
引用
- Rugo HS, Kok M, Goncalves A, et al. Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study. Ann Oncol. 2026. PMID: 42926111. doi:10.1016/j.annonc.2026.10.1285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。